PE20121438A1 - Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a - Google Patents
Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10aInfo
- Publication number
- PE20121438A1 PE20121438A1 PE2012000365A PE2012000365A PE20121438A1 PE 20121438 A1 PE20121438 A1 PE 20121438A1 PE 2012000365 A PE2012000365 A PE 2012000365A PE 2012000365 A PE2012000365 A PE 2012000365A PE 20121438 A1 PE20121438 A1 PE 20121438A1
- Authority
- PE
- Peru
- Prior art keywords
- lower alkyl
- alcoxy
- fluoroalkyl
- imidazo
- pyridin
- Prior art date
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title 1
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 title 1
- 150000005232 imidazopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 abstract 1
- -1 MORPHOLINE-4-CARBONYL Chemical class 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UN COMPUESTO DERIVADO DE IMIDAZOPIRIDINA DE FORMULA (I) DONDE: A ES N O C(R6); R1 ES H, ALQUILO INFERIOR O FLUOROALQUILO INFERIOR; R2 ES HALOGENO, C(O)NR7R8 O C(O)OR9; R3 ES H, ALQUILO INFERIOR, ALCOXI INFERIOR, FLUORO-ALCOXI INFERIOR, ENTRE OTROS; R4 ES H, ALQUILO INFERIOR, FLUOROALQUILO INFERIOR, ALCOXI INFERIOR, ENTRE OTROS; R5 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO POR 1 A 3 SUSTITUYENTES SELECCIONADOS ENTRE ALQUILO INFERIOR, ALCOXI INFERIOR, ENTRE OTROS; R6 ES H, HALOGENO, CN, CICLOALQUILO, ENTRE OTROS; R7 Y R8 SON INDEPENDIENTEMENTE H, ALQUILO INFERIOR, CICLOALQUILO, FLUOROALQUILO INFERIOR, ENTRE OTROS; R9 ES H, ALQUILO INFERIOR O FLUOROALQUILO INFERIOR; SON COMPUESTOS PREFERIDOS: (2-FENIL-IMIDAZO[1,2-a]PIRIDIN-7-IL)-AMIDA DEL ACIDO 4-CLORO-2-METIL-2H-PIRAZOL-3-CARBOXILICO; 4-DIMETILAMIDA 3-[(2-FENIL-IMIDAZO[1,2-a]PIRIDIN-7-IL)-AMIDA] DEL ACIDO 2-METIL-2H-PIRAZOL-3,4-DICARBOXILICO; (2-FENIL-IMIDAZO[1,2-a]PIRIDIN-7-IL)-AMIDA DEL ACIDO 2-METIL-4-(MORFOLINA-4-CARBONIL)-2H-PIRAZOL-3-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION. DICHO COMPUESTO ES UN INHIBIDOR DE LA ENZIMA PDE10A, SIENDO UTIL EN EL TRATAMIENTO DE LA ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, ESCLEROSIS MULTIPLE, APOPLEJIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09171253 | 2009-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121438A1 true PE20121438A1 (es) | 2012-10-26 |
Family
ID=43416552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000365A PE20121438A1 (es) | 2009-09-24 | 2010-09-21 | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8017604B2 (es) |
| EP (1) | EP2480546B1 (es) |
| JP (1) | JP5629322B2 (es) |
| KR (1) | KR101426624B1 (es) |
| CN (1) | CN102548991B (es) |
| AR (1) | AR078437A1 (es) |
| BR (1) | BR112012006531A2 (es) |
| CA (1) | CA2770087C (es) |
| CL (1) | CL2012000708A1 (es) |
| CY (1) | CY1116120T1 (es) |
| DK (1) | DK2480546T3 (es) |
| ES (1) | ES2530884T3 (es) |
| HR (1) | HRP20150345T1 (es) |
| IL (1) | IL218032A (es) |
| MX (1) | MX2012003469A (es) |
| PE (1) | PE20121438A1 (es) |
| PH (1) | PH12012500355A1 (es) |
| PL (1) | PL2480546T3 (es) |
| PT (1) | PT2480546E (es) |
| RU (1) | RU2502737C2 (es) |
| SI (1) | SI2480546T1 (es) |
| TW (1) | TWI402268B (es) |
| WO (1) | WO2011036127A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| KR20140048079A (ko) | 2011-02-01 | 2014-04-23 | 교와 핫꼬 기린 가부시키가이샤 | 축환 복소환 유도체 |
| WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| EP2574607A1 (en) * | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE10 modulators |
| BR112014006248A2 (pt) * | 2011-09-19 | 2017-04-11 | Hoffmann La Roche | compostos de triazolopiridina como inibidores de pde10a |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| EP2951176A1 (en) * | 2013-01-31 | 2015-12-09 | F. Hoffmann-La Roche AG | Radiolabeled compounds |
| TR201904614T4 (en) | 2013-02-27 | 2019-05-21 | Mochida Pharm Co Ltd | Novel pyrazole derivative. |
| RU2015147450A (ru) | 2013-04-29 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА |
| CN105164126B (zh) * | 2013-04-30 | 2017-05-31 | 豪夫迈·罗氏有限公司 | 吡唑酰胺的Pd‑催化偶联 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| KR101770532B1 (ko) | 2013-09-26 | 2017-08-22 | 에프. 호프만-라 로슈 아게 | 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민 |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| CN113698406A (zh) * | 2021-08-30 | 2021-11-26 | 成都药明康德新药开发有限公司 | 6-甲基吡唑并[1,5-a]嘧啶-3-胺的合成方法 |
| UY40979A (es) * | 2023-11-21 | 2025-06-30 | Novartis Ag | Iimidazoarenos sustituidos, composición farmacéutica que los comprende y método para la formación de un complejo que los comprende |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610697B1 (en) * | 1999-11-10 | 2003-08-26 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| SE0102808D0 (sv) * | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| ES2393333T3 (es) * | 2002-07-12 | 2012-12-20 | Astellas Pharma Inc. | Derivado de N-fenil-(2R,5S)dimetilpiperazina |
| EP1570847B1 (en) * | 2002-12-03 | 2012-04-25 | Kyorin Pharmaceutical Co., Ltd. | Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| US7566781B2 (en) * | 2004-05-10 | 2009-07-28 | Banyu Pharmaceutical Co., Ltd. | Imidazopyridine compound |
| US7998974B2 (en) * | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| KR101062583B1 (ko) * | 2006-01-17 | 2011-09-06 | 에프. 호프만-라 로슈 아게 | Ｇａｂａ 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-ａ]피리딘 |
| MX2008010668A (es) | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| DE102007012645A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
-
2010
- 2010-09-21 MX MX2012003469A patent/MX2012003469A/es active IP Right Grant
- 2010-09-21 PE PE2012000365A patent/PE20121438A1/es not_active Application Discontinuation
- 2010-09-21 CN CN201080042292.5A patent/CN102548991B/zh not_active Expired - Fee Related
- 2010-09-21 ES ES10760968T patent/ES2530884T3/es active Active
- 2010-09-21 HR HRP20150345TT patent/HRP20150345T1/hr unknown
- 2010-09-21 JP JP2012530234A patent/JP5629322B2/ja not_active Expired - Fee Related
- 2010-09-21 BR BR112012006531A patent/BR112012006531A2/pt not_active IP Right Cessation
- 2010-09-21 PH PH1/2012/500355A patent/PH12012500355A1/en unknown
- 2010-09-21 PL PL10760968T patent/PL2480546T3/pl unknown
- 2010-09-21 RU RU2012113128/04A patent/RU2502737C2/ru not_active IP Right Cessation
- 2010-09-21 PT PT107609687T patent/PT2480546E/pt unknown
- 2010-09-21 US US12/886,657 patent/US8017604B2/en not_active Expired - Fee Related
- 2010-09-21 WO PCT/EP2010/063830 patent/WO2011036127A1/en not_active Ceased
- 2010-09-21 DK DK10760968.7T patent/DK2480546T3/en active
- 2010-09-21 KR KR1020127010422A patent/KR101426624B1/ko not_active Expired - Fee Related
- 2010-09-21 CA CA2770087A patent/CA2770087C/en not_active Expired - Fee Related
- 2010-09-21 TW TW099132094A patent/TWI402268B/zh not_active IP Right Cessation
- 2010-09-21 EP EP10760968.7A patent/EP2480546B1/en not_active Not-in-force
- 2010-09-21 SI SI201030869T patent/SI2480546T1/sl unknown
- 2010-09-23 AR ARP100103465A patent/AR078437A1/es not_active Application Discontinuation
-
2011
- 2011-06-02 US US13/151,310 patent/US8263584B2/en not_active Expired - Fee Related
-
2012
- 2012-02-09 IL IL218032A patent/IL218032A/en not_active IP Right Cessation
- 2012-03-22 CL CL2012000708A patent/CL2012000708A1/es unknown
-
2015
- 2015-03-16 CY CY20151100263T patent/CY1116120T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| PE20121614A1 (es) | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 | |
| PE20081612A1 (es) | Analogos de las pterinas | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
| PE20130457A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| PE20130346A1 (es) | Compuestos heterociclicos fusionados | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| PE20121529A1 (es) | Compuestos derivados de piridopirimidina como inhibidores de pde4 | |
| PE20120110A1 (es) | [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20091211A1 (es) | Derivados de pirazolopirimidina como moduladores de pde9a | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |